PTC Therapeutics (PTCT) Misses Q1 EPS by 24c

PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.78), $0.24 worse than the analyst estimate of ($1.54). Revenue for the quarter came in at $148.73 million versus the consensus estimate of $146.9 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance